-
公开(公告)号：EP2459594A1
公开(公告)日：2012-06-06
申请号：EP10737222.9
申请日：2010-07-26
申请人： N.V. Organon , Medarex, Inc.
发明人： MATARAZA, Jennifer, Marie , VAN ELSAS, Andrea , KORMAN, Alan, J. , HALK, Edward, L. , THUDIUM, Kent, B. , SELBY, Mark , SPROUL, Timothy, W. , LEBLANC, Heidi, N.
IPC分类号： C07K16/28 , A61K39/395 , A61P37/06
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/2818 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/77 , C07K2317/92
摘要： The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
-
公开(公告)号：EP1212422B1
公开(公告)日：2007-02-21
申请号：EP00959399.7
申请日：2000-08-24
申请人： MEDAREX, INC.
IPC分类号： C12N15/13 , C07K16/28 , A61K39/395 , A01K67/027 , C12N5/10 , C12N5/20 , A61K39/00 , A61K38/19 , A61P35/00
CPC分类号： C12N15/8509 , A01K67/0276 , A01K67/0278 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/01 , A01K2267/0325 , A61K2039/505 , C07K16/2818 , C07K2317/21 , C07K2317/732 , C07K2319/00 , Y02A50/386 , Y02A50/403 , Y02A50/407 , Y02A50/41 , Y02A50/412 , Y02A50/466
摘要： The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
-
3.发明公开HUMAN ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF 有权淋巴细胞活化-3（LAG-3）结合人抗体及其用途
公开(公告)号：EP2320940A2
公开(公告)日：2011-05-18
申请号：EP09807162.4
申请日：2009-08-11
申请人： Medarex, Inc.
发明人： THUDIUM, Kent, B. , KORMAN, Alan, J. , LEBLANC, Heidi , YAMANAKA, Mark , SELBY, Mark , ZENS, Kyra, D.
IPC分类号： A61K39/00 , C07K17/00 , A61K39/395
CPC分类号： C07K16/2803 , A61K2039/505 , A61K2039/507 , C07K16/2827 , C07K2317/21 , C07K2317/34 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present disclosure provides isolated human monoclonal antibodies and antigen-binding portions thereof that bind to human LAG-3, in particular antibodies and antigen-binding antibody portions that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies and antigen-binding antibody portions of the invention as well as compositions and immunoconjugates of the antibodies and antigen-binding antibody portions of the invention are also provided. This disclosure also provides for the use of the antibodies and antigen-binding antibody portions of the invention in therapy.
-
公开(公告)号：EP1907424A2
公开(公告)日：2008-04-09
申请号：EP06786260.7
申请日：2006-06-30
申请人： MEDAREX, INC.
发明人： KORMAN, Alan, J. , SELBY, Mark, J. , WANG, Changyu , SRINIVASAN, Mohan , PASSMORE, David, B. , HUANG, Haichun , CHEN, Haibin
IPC分类号： C07K16/28
CPC分类号： C07K16/2827 , A61K45/06 , A61K47/6817 , A61K47/6825 , A61K47/6849 , A61K2039/505 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K2317/21 , C07K2317/41 , C07K2317/56 , C07K2317/567 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/77 , C07K2317/92 , Y02A50/386 , Y02A50/403 , Y02A50/407 , Y02A50/41 , Y02A50/412 , Y02A50/466
摘要： The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-Ll with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-Ll, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-Ll antibodies.
-
5.发明公开HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1(PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS 审中-公开人单克隆抗体程序性细胞死亡1（PD-1），和方法仅仅考虑用于癌症治疗的抗PD-1抗体或与其他免疫治疗学组合
公开(公告)号：EP1896582A1
公开(公告)日：2008-03-12
申请号：EP06746353.9
申请日：2006-05-02
发明人： KORMAN, Alan, J. , SRINIVASAN, Mohan , WANG, Changyu , SELBY, Mark, J. , CHEN, Bing , CARDARELLI, Josephine, M.
CPC分类号： A61K39/39558 , A61K39/00 , A61K39/3955 , A61K47/6849 , A61K51/10 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
-
公开(公告)号：EP1212422A2
公开(公告)日：2002-06-12
申请号：EP00959399.7
申请日：2000-08-24
申请人： MEDAREX, INC.
IPC分类号： C12N15/13 , C07K16/28 , A61K39/395 , A01K67/027 , C12N5/10 , C12N5/20 , A61K39/00 , A61K38/19 , A61P35/00
CPC分类号： C12N15/8509 , A01K67/0276 , A01K67/0278 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/01 , A01K2267/0325 , A61K2039/505 , C07K16/2818 , C07K2317/21 , C07K2317/732 , C07K2319/00 , Y02A50/386 , Y02A50/403 , Y02A50/407 , Y02A50/41 , Y02A50/412 , Y02A50/466
摘要： The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
-
公开(公告)号：EP2046834A1
公开(公告)日：2009-04-15
申请号：EP07792618.6
申请日：2007-08-10
发明人： POGUE, Sarah, L. , KORMAN, Alan, J. , CARDARELLI, Josephine, M. , SRINIVASAN, Mohan , CHEN, Bingliang , BELL, Alasdair, F.
IPC分类号： C07K16/24 , A61K39/395 , A61P3/10 , A61P9/10 , A61P29/00 , A61P35/00 , A61P37/00 , A61P37/06 , A61P43/00 , C12P21/08
CPC分类号： C07K16/24 , A61K2039/505 , C07K2299/00 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to SDF-1 with high affinity. Nucleic acid molecules encoding SDF-1 antibodies, expression vectors, host cells and methods for expressing the SDF-1 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the SDF-1 antibodies are also provided. Methods for detecting SDF-1, as well as methods for treating various B cell malignancies, including breast cancer, multiple myeloma and non-Hodgkin's lymphoma, and autoimmune disorders are disclosed.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.023 秒)
